Official Title
PRE-APPROVAL ACCESS (PAA) Single Patient Request (SPR) TREATMENT GUIDELINES for Teclistamab (JNJ-64007957) for Treating Physician Use
Brief Summary

Teclistamab pre-approval access in relapsed or refractory multiple myeloma.

Status
Available
EA Type
Individual Patients
Conditions
Multiple Myeloma
Interventions

Drug: Teclistamab
Teclistamab will be administered subcutaneously (SC).
Other Name: JNJ-64007957

Eligibility Criteria

Must have relapsed/refractory multiple myeloma (RRMM) and have evidence of disease
progression after last therapy. Must have exhausted all available treatment options
accessible as local standard of care (example. proteasome inhibitors [PIs],
immunomodulatory imide drugs [IMIDs], anti CD38 monoclonal antibodies [mAbs] and therapies
targeting Exportin 1 [XPO1] and B cell maturation antigen [BCMA]). Must not be eligible for
a clinical trial with teclistamab or other medicines in this setting

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years
Contacts

Contact
1-800-JANSSEN (1-800-526-7736)
Janssenmedinfo@its.jnj.com

Investigators

Janssen Research & Development, LLC Clinical Trial
Study Director
Janssen Research & Development, LLC

Sponsors / Collaborators
Janssen Research & Development, LLC
NCT Number
NCT05161598
MeSH Terms
Multiple Myeloma